Drug-eluting stent

Late-Breaking Data at EuroPCR: BIOTRONIK's Orsiro Demonstrates Unique Benefits in Small Vessels

Retrieved on: 
Tuesday, May 21, 2019
Medicine, Circulatory system, Clinical medicine, Interventional cardiology, Medical emergencies, Aging-associated diseases, RTT, Acute pain, Myocardial infarction, Coronary stent, Drug-eluting stent

In terms of cardiac death and myocardial infarction, the three stents showed similar results.

Key Points: 
  • In terms of cardiac death and myocardial infarction, the three stents showed similar results.
  • However, patients treated with the ultrathin strut Orsiro experienced significantly fewer repeat target lesion revascularizations (TLR) than those treated with the thin strut Resolute Integrity (Orsiro 2.1% vs. Resolute Integrity 5.3%, p=0.009; Synergy 4.0%).
  • While stenting of small coronary vessels is common, these patients are exposed to subsequent increased adverse cardiovascular event risks.
  • Three-year clinical outcome following treatment with thin, very thin or ultrathin strut DES in small coronary vessels in BIO-RESORT.

Elixir Medical to Present 9 and 12-Month Clinical and Imaging Data for the DynamX Bioadaptor, Showcasing the Next Frontier Beyond Stenting at EuroPCR 2019

Retrieved on: 
Tuesday, May 14, 2019
Health, Biotechnology, Hospitals, Medical devices, Pharmaceutical, Interventional cardiology, Medicine, Medical technology, Medical specialties, Medical devices, Drug-eluting stent, Stent, Cardiology, Percutaneous coronary intervention

EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

Key Points: 
  • EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
  • Conventional drug-eluting stents cage the coronary artery in a rigid, immobile frame inhibiting the vessels natural ability to expand in order to preserve the blood flow during disease progression.
  • Stents also impede the arterys physiologic pulsatility and hemodynamics during the cardiac cycle, potentially contributing to further adverse outcomes.
  • The company's next-generation systems are designed to restore the normal pulsatile motion and adaptive remodeling capabilities of the blood vessel.

Global Biodegradable Stents Markets, 2018-2019 & 2023 - R&D Issues, Global Regulatory Scenarios and Commercialization Hurdles

Retrieved on: 
Friday, May 3, 2019
Medical devices, Medicine, Medical technology, Polymers, Medical specialties, Interventional radiology, Stent, Interventional cardiology, Biodegradable polymer, Biomaterials, Bioresorbable stent, Drug-eluting stent

DUBLIN, May 3, 2019 /PRNewswire/ -- The "Biodegradable Stents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 3, 2019 /PRNewswire/ -- The "Biodegradable Stents: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report reviews both global and regional markets of the biodegradable stents market according to available types and application areas.
  • The analysis also discusses R&D issues, including global regulatory scenarios and other commercialization hurdles.
  • These devices, which have typical metallic nondegradable stent backbones, are known as bioresorbable polymer DES, bioabsorbable polymer DES or biodegradable polymer DES.

World Nasal Implants Market Projections 2019-2023 with Ethicon USA, Implantech, Intersect ENT, Stryker, and Zimmer Biomet Dominating - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2019
Professional services, Consulting, Medicine, Prosthetics, Medical technology, Biomedical engineering, Implant, Tissue engineering, Drug-eluting stent, Clinical medicine, Breast surgery

The nasal implants market will register a CAGR of 6% by 2023.

Key Points: 
  • The nasal implants market will register a CAGR of 6% by 2023.
  • The growing product launches of nasal implants incorporated with drug-eluting stents will drive the nasal implants market growth in the forthcoming years.
  • One of the growth drivers of the global nasal implants market is the growing demand for nasal implants for medical conditions and aesthetic procedures.
  • One of the challenges in the growth of global nasal implants market is the migration to a hosted environment.

The nasal implants market will register a CAGR of 6% by 2023

Retrieved on: 
Tuesday, April 16, 2019
Medicine, Prosthetics, Medical technology, Biomedical engineering, Implant, Tissue engineering, Drug-eluting stent, Clinical medicine, Breast surgery

The growing product launches of nasal implants incorporated with drug-eluting stents will drive the nasal implants market growth in the forthcoming years.

Key Points: 
  • The growing product launches of nasal implants incorporated with drug-eluting stents will drive the nasal implants market growth in the forthcoming years.
  • Analysts have predicted that the nasal implants market will register a CAGR of 6% by 2023.
  • One of the growth drivers of the global nasal implants market is the growing demand for nasal implants for medical conditions and aesthetic procedures.
  • One of the challenges in the growth of global nasal implants market is the migration to a hosted environment.

HonorHealth Research Institute launches study to research benefit to patients at high risk of bleeding after coronary stent implantation

Retrieved on: 
Tuesday, April 16, 2019
Medicine, Interventional cardiology, Medical specialties, Clinical medicine, Antiplatelet drug, Coronary stent, RTT, Aging-associated diseases, Percutaneous coronary intervention, Drug-eluting stent, Medical emergencies

SCOTTSDALE, Ariz., April 16, 2019 /PRNewswire/ -- HonorHealth Research Institute announced that the first patients have been enrolled in the SynIVUS-DAPT Study , a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet medications after receiving a drug-eluting coronary stent.

Key Points: 
  • SCOTTSDALE, Ariz., April 16, 2019 /PRNewswire/ -- HonorHealth Research Institute announced that the first patients have been enrolled in the SynIVUS-DAPT Study , a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet medications after receiving a drug-eluting coronary stent.
  • "These medications can exacerbate bleeding risk and therefore, being able to reduce the amount of time patients are on these dual antiplatelet regimens can be beneficial."
  • All five HonorHealth hospitals in the greater Phoenix area are participating in the study.
  • Are at risk for falling or other conditions that may put them at a high risk of bleeding.

Analysis on the World Market for Biodegradable Stents, 2019 to 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 16, 2019
Health, Medical devices, Medicine, Medical technology, Polymers, Medical specialties, Interventional radiology, Stent, Interventional cardiology, Biodegradable polymer, Biomaterials, Bioresorbable stent, Drug-eluting stent

This report reviews both global and regional markets of the biodegradable stents market according to available types and application areas.

Key Points: 
  • This report reviews both global and regional markets of the biodegradable stents market according to available types and application areas.
  • The report analyzes the current market status and trends, and provides growth forecasts for the five-year period 2018 to 2023.
  • These devices, which have typical metallic nondegradable stent backbones, are known as bioresorbable polymer DES, bioabsorbable polymer DES or biodegradable polymer DES.
  • Therefore, this report concentrates only on the BDS market for fully bioabsorbable or biodegradable stents.

Global Coronary Stent Market Trends, and Forecasts 2019-2024: Increasing Prevalence of Coronary Artery Diseases (CADs) Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 15, 2019
Health, Medical devices, Medicine, Cardiovascular system, Circulatory system, Medical devices, Interventional cardiology, Interventional radiology, Heart diseases, Coronary artery disease, Stent, Coronary stent, Percutaneous coronary intervention, Drug-eluting stent

The major factors found propelling the growth of the market include the increasing prevalence of coronary artery diseases (CADs), rising the geriatric population, and the technological advancements in coronary stents.

Key Points: 
  • The major factors found propelling the growth of the market include the increasing prevalence of coronary artery diseases (CADs), rising the geriatric population, and the technological advancements in coronary stents.
  • The prevalence of coronary artery disease (CAD) has increased in the past three decades in the low- and middle-income countries, including India.
  • Thus the burden of CAD has increased and has boosted the usage of coronary stents, thus helping in driving the market growth.
  • There has also been a high demand for minimally invasive surgical procedures that is likely to significantly drive the coronary stent market.

Global Drug Eluting Stents Markets, 2024

Retrieved on: 
Monday, April 8, 2019
Organic compounds, Medicine, Interventional cardiology, Medical specialties, Drug-eluting stent, Stent, Everolimus, Paclitaxel, Percutaneous coronary intervention, Steroid eluting sinus stent

DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Drug Eluting Stents Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Drug Eluting Stents Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.
  • The Global Drug-Eluting Stents Market is Expected to Witness a CAGR of 5.4% During the Forecast Period to Reach Revenue of $5,614.6 Million by 2024.
  • Drug-eluting stents refer to the metal stents that have a coating of drugs such as paclitaxel, everolimus, and also antiproliferative drugs to widen the narrowed blood vessel.
  • The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals.

Global Drug Eluting Stents Market 2018-2019 & 2024 - Growing Acceptance for Minimally Invasive Endovascular Surgeries - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2019
Surgery, Health, Medical devices, Pharmaceutical, Medicine, Medical specialties, Interventional cardiology, Health care, Drug-eluting stent, Stent, Outpatient surgery, Cardiology, Percutaneous coronary intervention, Bioresorbable stent

However, thrombosis, along with vasomotion, is the major issue that needs to be addressed in the DES market.

Key Points: 
  • However, thrombosis, along with vasomotion, is the major issue that needs to be addressed in the DES market.
  • Increasing prevalence of cardiovascular diseases, rising aging population, growing acceptance for minimally invasive endovascular surgeries, and good reimbursement facilities are few of the factors driving the growth of the DES market.
  • Europe accounts for the largest share of the drug-eluting stents market, followed by Europe, Asia Pacific, and Rest of the World.
  • The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals.